2023  1,500
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 54(2020) N 6 p. 827-839; DOI 10.1134/S0026893320060060 Full Text

N.V. Katolikova1,2*, A.B. Malashicheva2,3, R.R. Gainetdinov1,4

Cell Replacement Therapy in Parkinson's Disease-History of Development and Prospects for Use in Clinical Practice

1Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, 199034 Russia
2Institute of Cytology, Russian Academy of Sciences, St. Petersburg, 194064 Russia
3Almazov National Medical Research Centre, Ministry of Health of Russian Federation, St. Petersburg, 197341 Russia
4Pirogov Clinic of High Medical Technologies, St. Petersburg State University, St. Petersburg, 199034 Russia

Received - 2020-04-23; Revised - 2020-06-16; Accepted - 2020-06-25

Parkinson's disease is a widespread neurodegenerative disease, which is characterized by the death of dopaminergic neurons in the substantia nigra of the midbrain. Clinically, the disease is manifested by tremor, bradykinesia, muscle rigidity, and other motor and non-motor symptoms that ultimately lead to disability. To date, there are only symptomatic treatment options for Parkinson's disease; therefore, the search for new approaches is one of the most important directions of therapy for this disease. In the 1970's the idea of using cell replacement therapy based on the local nature and specificity of damage to a particular type of neuron in Parkinson's disease originated. The selection of the source of cells, the method and place of introduction, indications for this operation, and peculiarities of patient management have been in development for a long time. The efficiency of cell replacement therapy has been confirmed by a number of studies on animal models. Clinical trials have already begun and several more are planned soon. This review describes the main prerequisites for the use of cell replacement therapy in Parkinson's disease, the stages of development of this method, and clinical trials that have started in the last few years.

Parkinson's disease, cell replacement therapy, embryonic stem cells, induced pluripotent stem cells, cell differentiation, neuronal progenitors